keyword
MENU ▼
Read by QxMD icon Read
search

Antipsychotic Weight Gain

keyword
https://www.readbyqxmd.com/read/29122637/side-effect-burden-of-antipsychotic-drugs-in-real-life-impact-of-gender-and-polypharmacy
#1
Trude Seselie Jahr Iversen, Nils Eiel Steen, Ingrid Dieset, Sigrun Hope, Ragni Mørch, Erlend Strand Gardsjord, Kjetil Nordbø Jørgensen, Ingrid Melle, Ole A Andreassen, Espen Molden, Erik G Jönsson
BACKGROUND: Antipsychotic-associated side effects are well known and represent a significant treatment challenge. Still, few large studies have investigated the overall side effect burden of antipsychotics in real-life settings. OBJECTIVE: To describe the occurrence of side effects and perceived burden of antipsychotics in a large naturalistic sample, taking polypharmacy and patient characteristics into account. METHOD: Patients (n=1087) with psychotic disorders were assessed for side effects using the Udvalg for Kliniske Undersøgelser (UKU) side effect rating scale in addition to assessment of clinical and pharmacological data...
November 6, 2017: Progress in Neuro-psychopharmacology & Biological Psychiatry
https://www.readbyqxmd.com/read/29119689/decreased-5-ht2cr-and-ghsr1a-interaction-in-antipsychotic-drug-induced-obesity
#2
REVIEW
X-F Huang, K Weston-Green, Y Yu
Second generation antipsychotics (SGAs), notably atypical antipsychotics including olanzapine, clozapine and risperidone, can cause weight gain and obesity side effects. Antagonism of serotonin 2c receptors (5-HT2cR) and activation of ghrelin receptor type 1a (GHSR1a) signalling have been identified as a main cause of SGA induced obesity. Here we review the pivotal regulatory role of the 5-HT2cR in ghrelin-mediated appetite signalling. The 5-HT2cR dimerizes with GHSR1a to inhibit orexigenic signalling, while 5-HT2cR antagonism reduces dimerization and increases GHSR1a-induced food intake...
November 9, 2017: Obesity Reviews: An Official Journal of the International Association for the Study of Obesity
https://www.readbyqxmd.com/read/29116126/development-of-multivariable-models-to-predict-change-in-body-mass-index-within-a-clinical-trial-population-of-psychotic-individuals
#3
Rebecca N S Harrison, Fiona Gaughran, Robin M Murray, Sang Hyuck Lee, Jose Paya Cano, David Dempster, Charles J Curtis, Danai Dima, Hamel Patel, Simone de Jong, Gerome Breen
Many antipsychotics promote weight gain, which can lead to non-compliance and relapse of psychosis. By developing models that accurately identify individuals at greater risk of weight gain, clinicians can make informed treatment decisions and target intervention measures. We examined clinical, genetic and expression data for 284 individuals with psychosis derived from a previously published randomised controlled trial (IMPACT). These data were used to develop regression and classification models predicting change in Body Mass Index (BMI) over one year...
November 7, 2017: Scientific Reports
https://www.readbyqxmd.com/read/29093685/bipolar-spectrum-disorders-in-male-youth-the-interplay-between-symptom-severity-inflammation-steroid-secretion-and-body-composition
#4
REVIEW
Andreas Walther, Marlene Penz, Daniela Ijacic, Timothy R Rice
The morbidity and societal burden of youth bipolar spectrum disorders (BSD) are high. These disorders are multisystemic in that adult populations there are clear interactions with inflammatory processes and steroidal physiological systems. There are much less data concerning these areas of study in youth populations with BSD. This is surprising given the association of youth-onset BSD with puberty and its associated physiological changes. In this mini-review, we overview the theoretical role of inflammatory processes and steroidal physiological systems in youth BSD, describe the greater literature in adult populations, detail the literature in youth populations when available, and overview current proposed molecular mechanistic pathways and interaction effects based on the available data...
2017: Frontiers in Psychiatry
https://www.readbyqxmd.com/read/29083297/in-male-rats-the-ability-of-central-insulin-to-suppress-glucose-production-is-impaired-by-olanzapine-whereas-glucose-uptake-is-left-intact
#5
Chantel Kowalchuk, Celine Teo, Virginia Wilson, Araba Chintoh, Loretta Lam, Sri Mahavir Agarwal, Adria Giacca, Gary J Remington, Margaret K Hahn
BACKGROUND: Insulin receptors are widely expressed in the brain and may represent a crossroad between metabolic and cognitive disorders. Although antipsychotics, such as olanzapine, are the cornerstone treatment for schizophrenia, they are associated with high rates of type 2 diabetes and lack efficacy for illness-related cognitive deficits. Historically, this risk of diabetes was attributed to the weight gain propensity of antipsychotics, but recent work suggests antipsychotics can have weight-independent diabetogenic effects involving unknown brain-mediated mechanisms...
November 2017: Journal of Psychiatry & Neuroscience: JPN
https://www.readbyqxmd.com/read/29078988/gestational-weight-gain-and-pre-pregnancy-body-mass-index-associated-with-second-generation-antipsychotic-drug-use-during-pregnancy
#6
Marlene P Freeman, Alexandra Z Sosinsky, Lina Goez-Mogollon, Gina M Savella, Danna Moustafa, Adele C Viguera, Lee S Cohen
BACKGROUND: Obesity during pregnancy is the most common high-risk obstetric condition, resulting in increased rates of adverse maternal and neonatal outcomes. Individuals with psychiatric disorders have a higher risk of obesity than the general population, but data regarding implications of obesity in women with psychiatric disorders are sparse. OBJECTIVE: The objective of this study was to assess pre-pregnancy weights and gestational weight gain in women who were exposed to second-generation antipsychotics (SGAs) during pregnancy compared to controls...
September 21, 2017: Psychosomatics
https://www.readbyqxmd.com/read/29075309/weight-changes-before-and-after-lurasidone-treatment-a-real-world-analysis-using-electronic-health-records
#7
Jonathan M Meyer, Daisy S Ng-Mak, Chien-Chia Chuang, Krithika Rajagopalan, Antony Loebel
BACKGROUND: Severe and persistent mental illnesses, such as schizophrenia and bipolar disorder, are associated with increased risk of obesity compared to the general population. While the association of lurasidone and lower risk of weight gain has been established in short and longer-term clinical trial settings, information about lurasidone's association with weight gain in usual clinical care is limited. This analysis of usual clinical care evaluated weight changes associated with lurasidone treatment in patients with schizophrenia or bipolar disorder...
2017: Annals of General Psychiatry
https://www.readbyqxmd.com/read/29067671/a-review-of-asenapine-in-the-treatment-of-bipolar-disorder
#8
REVIEW
Eduard Vieta, José Manuel Montes
Bipolar disorder places a significant burden on the affected individuals, their family, healthcare systems and the overall economy. More treatment options are needed, especially those with better efficacy and tolerability. Asenapine is a second-generation antipsychotic approved in Europe (brand name Sycrest(®)) for the treatment of moderate-to-severe manic episodes associated with bipolar I disorder in adults, and in the US (brand name Saphris(®)) for the treatment of manic or mixed episodes of bipolar I disorder in adults and children aged 10-17 years...
October 24, 2017: Clinical Drug Investigation
https://www.readbyqxmd.com/read/29057817/unresolved-issues-for-utilization-of-atypical-antipsychotics-in-schizophrenia-antipsychotic-polypharmacy-and-metabolic-syndrome
#9
REVIEW
Sang Won Jeon, Yong-Ku Kim
Atypical antipsychotics (AAP) are the prevailing form of schizophrenia treatment today due to their low side effects and superior efficacy. Nevertheless, some issues still need to be addressed. First, there are still a large number of patients with treatment-resistant schizophrenia (TRS), which has led to a growing trend to resort to AAP polypharmacy with few side effects. Most clinical treatment guidelines recommend clozapine monotherapy in TRS, but around one third of schizophrenic patients fail to respond to clozapine...
October 18, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/29035174/in-male-rats-the-ability-of-central-insulin-to-suppress-glucose-production-is-impaired-by-olanzapine-whereas-glucose-uptake-is-left-intact
#10
Chantel Kowalchuk, Celine Teo, Virginia Wilson, Araba Chintoh, Loretta Lam, Sri Mahavir Agarwal, Adria Giacca, Gary J Remington, Margaret K Hahn
BACKGROUND: Insulin receptors are widely expressed in the brain and may represent a crossroad between metabolic and cognitive disorders. Although antipsychotics, such as olanzapine, are the cornerstone treatment for schizophrenia, they are associated with high rates of type 2 diabetes and lack efficacy for illness-related cognitive deficits. Historically, this risk of diabetes was attributed to the weight gain propensity of antipsychotics, but recent work suggests antipsychotics can have weight-independent diabetogenic effects involving unknown brain-mediated mechanisms...
October 16, 2017: Journal of Psychiatry & Neuroscience: JPN
https://www.readbyqxmd.com/read/29034440/risperidone-induced-metabolic-dysfunction-is-attenuated-by-curcuma-longa-extract-administration-in-mice
#11
Florent Auger, Françoise Martin, Olivier Pétrault, Jennifer Samaillie, Thierry Hennebelle, Mohamed-Sami Trabelsi, François Bailleul, Bart Staels, Régis Bordet, Patrick Duriez
Antipsychotics, such as risperidone, increase food intake and induce alteration in glucose and lipid metabolism concomitantly with overweight and body fat increase, these biological abnormalities belong to the metabolic syndrome definition (high visceral adiposity, hypertriglyceridemia, hyperglycemia, low HDL-cholesterol and high blood pressure). Curcumin is a major component of traditional turmeric (Curcuma longa) which has been reported to improve lipid and glucose metabolism and to decrease weight in obese mice...
October 16, 2017: Metabolic Brain Disease
https://www.readbyqxmd.com/read/29026311/artesunate-prevents-rats-from-the-clozapine-induced-hepatic-steatosis-and-elevation-in-plasma-triglycerides
#12
Yanmei Li, Ruibing Su, Shuqin Xu, Qingjun Huang, Haiyun Xu
Clozapine is an atypical antipsychotic with therapeutic efficacy in treatment-resistant schizophrenia patients and low incidence of extrapyramidal side effects. However, the use of clozapine has been limited by its adverse effects on metabolism. Artesunate is a semisynthetic derivative of artemisinin and was shown to decrease the plasma cholesterol and triglyceride in rabbits and rats in recent studies. The aim of this study was to examine possible effects of artesunate on the clozapine-induced metabolic alterations in rats given saline, clozapine, artesunate, or clozapine plus artesunate for 6 weeks...
2017: Neuropsychiatric Disease and Treatment
https://www.readbyqxmd.com/read/29020342/lack-of-ovarian-secretions-reverts-the-anabolic-action-of-olanzapine-in-female-rats
#13
Silje Skrede, Ismael González-García, Luís Martins, Rolf Kristian Berge, Ruben Nogueiras, Manuel Tena-Sempere, Gunnar Mellgren, Vidar Martin Steen, Miguel López, Johan Fernø
Background: Olanzapine (OLZ) is an orexigenic antipsychotic drug associated with serious metabolic adverse effects in humans. Development of valid rodent models for antipsychotic-induced metabolic adverse effects is hampered by the fact that such effects occur in females only. Estradiol (E2) is a predominant female hormone that regulates energy balance. We hypothesized that the female-specific hyperphagia and weight gain induced by OLZ in the rat are dependent on the presence of estrogens...
August 14, 2017: International Journal of Neuropsychopharmacology
https://www.readbyqxmd.com/read/29017334/brexpiprazole-a-new-leaf-on-the-partial-dopamine-agonist-branch
#14
Judy Hope, David Castle, Nicholas A Keks
OBJECTIVES: Brexpiprazole is a new dopamine partial agonist antipsychotic in the same class as aripiprazole. This paper will briefly review brexpiprazole and compare it with aripiprazole. CONCLUSIONS: Brexpiprazole and aripiprazole are both partial agonists at dopamine D2, and serotonin 5-HT1A and antagonists at serotonin 5-HT2A and noradrenergic α1B receptors. However, the two drugs are significantly different in potencies at various receptors; neurochemical profiles predict that brexpiprazole may be comparable with aripiprazole in its antipsychotic efficacy but may cause less akathisia, extrapyramidal side effects (EPS) and activation...
October 1, 2017: Australasian Psychiatry: Bulletin of Royal Australian and New Zealand College of Psychiatrists
https://www.readbyqxmd.com/read/28980344/association-between-antipsychotic-treatment-and-leptin-levels-across-multiple-psychiatric-populations-an-updated-meta-analysis
#15
Renee-Marie Ragguett, Margaret Hahn, Giovanni Messina, Sergio Chieffi, Marcellino Monda, Vincenzo De Luca
OBJECTIVE: Antipsychotics (APs) are associated with metabolic syndrome, with increases in leptin proposed as an underlying mechanism of AP-induced weight gain. Currently available meta-analyses on this topic have limited their populations of interest to those diagnosed with schizophrenia. The purpose of this meta-analysis is to explore the relationship between leptin levels and AP use across multiple psychiatric diagnoses, and also in healthy controls. METHOD: Systematic electronic searches were conducted using PubMed and OVID: Medline...
October 5, 2017: Human Psychopharmacology
https://www.readbyqxmd.com/read/28973118/liraglutide-for-the-treatment-of-antipsychotic-drug-induced-weight-gain
#16
Ariel Y Deutch
No abstract text is available yet for this article.
November 1, 2017: JAMA Psychiatry
https://www.readbyqxmd.com/read/28973062/liraglutide-for-the-treatment-of-antipsychotic-drug-induced-weight-gain-reply
#17
Anders Fink-Jensen, Christoph U Correll, Tina Vilsbøll
No abstract text is available yet for this article.
September 27, 2017: JAMA Psychiatry
https://www.readbyqxmd.com/read/28945118/psychopharmacological-treatment-in-the-raise-etp-study-outcomes-of-a-manual-and-computer-decision-support-system-based-intervention
#18
Delbert G Robinson, Nina R Schooler, Christoph U Correll, Majnu John, Benji T Kurian, Patricia Marcy, Alexander L Miller, Ronny Pipes, Madhukar H Trivedi, John M Kane
OBJECTIVE: The Recovery After an Initial Schizophrenia Episode-Early Treatment Program compared NAVIGATE, a comprehensive program for first-episode psychosis, to clinician-choice community care over 2 years. Quality of life and psychotic and depressive symptom outcomes were found to be better with NAVIGATE. Compared with previous comprehensive first-episode psychosis interventions, NAVIGATE medication treatment included unique elements of detailed first-episode-specific psychotropic medication guidelines and a computerized decision support system to facilitate shared decision making regarding prescriptions...
September 15, 2017: American Journal of Psychiatry
https://www.readbyqxmd.com/read/28942807/a-randomized-placebo-controlled-trial-of-metformin-for-the-treatment-of-overweight-induced-by-antipsychotic-medication-in-young-people-with-autism-spectrum-disorder-open-label-extension
#19
Benjamin L Handen, Evdokia Anagnostou, Michael G Aman, Kevin B Sanders, James Chan, Jill A Hollway, Jessica Brian, L Eugene Arnold, Lucia Capano, Craig Williams, Jessica A Hellings, Eric Butter, Deepali Mankad, Rameshwari Tumuluru, Jessica Kettel, Cassandra R Newsom, Naomi Peleg, Dina Odrobina, Sarah McAuliffe-Bellin, Sarah Marler, Taylor Wong, Alexis Wagner, Stasia Hadjiyannakis, Eric A Macklin, Jeremy Veenstra-VanderWeele
OBJECTIVE: A previous study reported on a 16-week placebo-controlled, randomized clinical trial (RCT) of metformin for weight stabilization in 61 children and adolescents 6 to 17 years old with autism spectrum disorder who were prescribed atypical antipsychotics. The present study describes the results of a 16-week open-label extension. METHOD: Fifty-two participants from the acute trial (85%) entered the extension; 22 had been on metformin during the initial RCT and 30 had been on placebo...
October 2017: Journal of the American Academy of Child and Adolescent Psychiatry
https://www.readbyqxmd.com/read/28942801/antipsychotic-induced-weight-gain-and-metformin
#20
EDITORIAL
John T Walkup, Elizabeth Cottingham
No abstract text is available yet for this article.
October 2017: Journal of the American Academy of Child and Adolescent Psychiatry
keyword
keyword
54097
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"